← All candidates
21 insider filings on record.
30 filings on record.
SPRYARS Pharmaceuticals, Inc.
NasdaqGM · Healthcare · $589.86M
$4.76
-0.96% · Sep 18
21 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 5 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$589.86M
Float
48.4M
49% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
6.0
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
16 more transactions on Pro →Context
Wall St
$28.80 avg target
+505.0% vs today · 5 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$0.61 act−$0.07
Q4 '25−$0.42 act+$0.06
Q3 '25−$0.52 act−$0.03
Q2 '25−$0.46 act+$0.05
Coverage
How The Evolving Story For ARS Pharmaceuticals (SPRY) Could Shape Future ValuationSimply Wall St. · 06-09ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby · 05-16ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...GuruFocus.com · 05-15ARS Pharmaceuticals Q1 Earnings Call Highlights
The file stays open
30 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice